Discuva, the drug discovery company developing antimicrobial therapies against drug-resistant pathogens, announced today that it has moved into new laboratories based on the Cambridge Science Park. This space will accommodate the growth of the new Biotechnology Company over the next five years.
David Williams, CEO of Discuva, said: “Having a laboratory base in Cambridge gives us the platform we need to continue to hire the best people to deliver our objective – providing new antimicrobial agents to help in the war against drug-resistant bacteria. The new labs will allow us to continue refining our technology and push forward our antimicrobial programmes.”
About Discuva Ltd
Discuva is a Cambridge, UK-based drug Discovery Company which was established to address the major gaps that exist in the current treatment of infective disease with antibiotics and meet the current, critical unmet medical need in the clinic. The company has proprietary technologies that allow the rapid identification and development of targeted Next Generation antibiotics against emerging and drug-resistant pathogens. Discuva currently has several specific antimicrobial programmes mainly focused on Gram negative bacteria that cause major hospital and community-based infections. The drugs produced by Discuva are being developed to have two major advantages over conventional antibiotics; no development of cross resistance and fewer side effects giving safer more effective treatments with a longer market life.
*******
Contact:
David Williams, PhD
Chief Executive Officer
Discuva Limited
Tel: +44(0)1223 394200
info@discuva.com
Article written by Discuva Limited.